XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment … Read more
XORTX Therapeutics Inc (XRTX) - Total Liabilities
Latest total liabilities as of December 2025: $820.51K USD
Based on the latest financial reports, XORTX Therapeutics Inc (XRTX) has total liabilities worth $820.51K USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
XORTX Therapeutics Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how XORTX Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
XORTX Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of XORTX Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Patriot Resources Ltd
AU:PAT
|
Australia | AU$86.68K |
|
Agro Yasa Lestari PT Tbk
JK:AYLS
|
Indonesia | Rp150.95 Million |
|
Unifin Financiera S. A. B. de C. V
MX:UNIFINA
|
Mexico | MX$83.80 Billion |
|
NovaBay Pharmaceuticals Inc
NYSE MKT:NBY
|
USA | $1.85 Million |
|
M8 Sustainable Ltd
AU:M8S
|
Australia | AU$13.60 Million |
|
Ictsi Jasa Prima Tbk
JK:KARW
|
Indonesia | Rp47.48 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down XORTX Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how XORTX Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for XORTX Therapeutics Inc (2014–2025)
The table below shows the annual total liabilities of XORTX Therapeutics Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $820.51K | +8.25% |
| 2024-12-31 | $757.99K | -8.23% |
| 2023-12-31 | $825.94K | -84.62% |
| 2022-12-31 | $5.37 Million | +1.59% |
| 2021-12-31 | $5.28 Million | +551.61% |
| 2020-12-31 | $811.04K | -37.60% |
| 2019-12-31 | $1.30 Million | +37.72% |
| 2018-12-31 | $943.70K | -17.60% |
| 2017-12-31 | $1.15 Million | +91.02% |
| 2016-12-31 | $599.52K | +896.52% |
| 2014-12-31 | $60.16K | -- |